Treatment of knee osteoarthritis with combination of traumeel s and zeel t: review mozart clinical investigation

Sergey Popovich

Abstract


Traditional treatment of osteoarthritis is focused on the symptoms’ decrease using pain-killers, nonsteroid anti-inflammatory drugs (NSAIDs), intraarticular corticosteroid injections, hyaluronic acid and so on. Nevertheless, such a therapy has some limitation due to the possible side effects and contraindications, especially in elderly people with concomitant diseases. Traumeel S consists of 14 components with vegetal and mineral origins, that determine its anti-inflammatory, anti-exudative, anesthetic, restorative and immune-modeling action. Zeel T provides chondroprotective, anti-inflammatory, anesthetic effects that promotes restoration of metabolic and reparative processes in joint cartilage. Goal: to expose the results of multicenter randomized placebo-control double-blind investigation MOZArT («Management of Оsteoarthritis of the Knee with Zeel and Traumeel Injections») to evaluate the efficacy and safety of the intraarticular injections of Traumeel S and Zeel T in comparison with placebo. The methods: 232 patients from 24 centers in USA were involved in the investigation. Patients (119) from the main group took the injection of Traumeel S and Zeel T, 113 participants from control group – physiological solution as a placebo. Three injection of every remedy were carried out with 1-week interval between the injections. WOMAC A scale was used to assess the results. Results: under the conditions of Traumeel S and Zeel T usage significant reducing of pain by 60 % according to WOMAC A scale was observed after 2nd injection and during the following 12 weeks. The effect of mentioned combined therapy was compared with the results of intra-articular corticosteroid and hyaluronic acid injection and peroral diclofenac. Safety profiles of Traumeel S and Zeel T were more optimal in comparison with peroral NSAIDs, without any risk from cardiac-vascular and gastro-intestinal systems.

Keywords


osteoarthritis; knee joint; Traumeel S; Zeel T; intraarticular injections; MOZArT investigation

References


A multi-center double-blind, randomized, controlled trial (db-RCT) to evaluate the effectiveness and safety of co-administered Traumeel® (Tr14) and Zeel® (Ze14) intra-articular (IA) injections versus IA placebo in patients with moderate-to-serve pain associated with OA of the knee / C. Lozada, E. del Rio, D. Reitberg [et al.] / Arthritis Rheumatol. — 2014. — Vol. 66, Ssuppl. — P. S1266.

Monograph of Traumeel S/ Ed. from English. — M.: Arnebia, 2015. — 80 p.

WOMAC Osteoarthritis Index [web source]. — Access mode: http://www.womac.org/womac/index.htm.

Traumeel vs. diclofenac for reducing pain and improving ankle mobility after acute ankle sprain: A multicentre, randomised, blinded, controlled and non-inferiority trial / C. González de Vega, C. Speed, B. Wolfarth, J. González // Int. J. Clin. Pract. — 2013. — Vol. 67 (10). — P. 979–989, doi: 10.1111/ijcp.12219.

Comparative effectiveness of pharmacologic interventions for knee osteoarthritis a systematic review and network meta-analysis / R. R. Bannuru, Ch. H. Schmid, D. M. Kent [et al.] // Ann. Intern. Med. — 2015. — Vol. 162. — P. 46–54, doi: 10.7326/M14-1231.

Risk-Benefit of Co-Administered Traumeel® (TR14) and Zeel® (ZE14) Intra-Articular (IA) Injections in Patients with Moderate-to-Severe Pain Associated with OA of the Knee (OAK). Poster Presentations THU0441 / C. Lozada, E. del Rio, D. P. Reitberg [et al.]: materials of Annual European Congress EULAR (Rome, 10-13.06.2015) // Ann Rheum Dis. — 2015. — Vol. 74, Suppl. 2. — P. 359, doi: 10.1136/annrheumdis-2015-eular.4268.

The purpose of the Zeel T: Product of monograph / Ed. from English. — Germany, Baden-Baden, Biologische Heilmittel Heel GmbH, 2015. — 56 p.




DOI: https://doi.org/10.15674/0030-59872015481-84

Refbacks

  • There are currently no refbacks.


Copyright (c) 2015 Sergey Popovich

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.